Equities research analysts predict that Miragen Therapeutics, Inc. (NASDAQ:MGEN) will report earnings per share of ($0.32) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Miragen Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.28) and the lowest estimate coming in at ($0.41). Miragen Therapeutics posted earnings of ($7.72) per share during the same quarter last year, which would indicate a positive year over year growth rate of 95.9%. The business is scheduled to announce its next earnings report on Friday, March 23rd.
On average, analysts expect that Miragen Therapeutics will report full-year earnings of ($1.35) per share for the current financial year, with EPS estimates ranging from ($1.62) to ($0.98). For the next year, analysts forecast that the firm will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.72) to ($1.29). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Miragen Therapeutics.
A number of research firms recently issued reports on MGEN. Cann reaffirmed a “buy” rating and issued a $13.00 price target on shares of Miragen Therapeutics in a report on Friday, February 2nd. Zacks Investment Research cut Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 25th. Chardan Capital reaffirmed a “buy” rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. Oppenheimer began coverage on Miragen Therapeutics in a report on Friday, January 12th. They issued an “outperform” rating and a $13.00 price target for the company. Finally, B. Riley began coverage on Miragen Therapeutics in a report on Friday, January 5th. They issued a “buy” rating and a $15.50 price target for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $16.46.
Shares of Miragen Therapeutics (MGEN) traded down $0.23 during midday trading on Tuesday, hitting $5.59. The company’s stock had a trading volume of 319,500 shares, compared to its average volume of 307,998. The company has a market capitalization of $161.48, a PE ratio of 36.93 and a beta of 1.43. Miragen Therapeutics has a 12 month low of $5.01 and a 12 month high of $18.00. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.11 and a current ratio of 7.11.
In other Miragen Therapeutics news, insider Adam Scott Levy purchased 9,090 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The stock was acquired at an average cost of $5.50 per share, with a total value of $49,995.00. Following the completion of the acquisition, the insider now directly owns 10,540 shares of the company’s stock, valued at approximately $57,970. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Thomas E. Hughes sold 12,000 shares of Miragen Therapeutics stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $8.00, for a total value of $96,000.00. The disclosure for this sale can be found here. Insiders own 44.40% of the company’s stock.
Large investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in Miragen Therapeutics during the 3rd quarter worth about $250,000. BSW Wealth Partners bought a new stake in Miragen Therapeutics during the 3rd quarter worth about $203,000. Seaward Management Limited Partnership bought a new stake in Miragen Therapeutics during the 3rd quarter worth about $117,000. Aveo Capital Partners LLC bought a new stake in Miragen Therapeutics during the 4th quarter worth about $279,000. Finally, Russell Investments Group Ltd. bought a new stake in Miragen Therapeutics during the 3rd quarter worth about $147,000. 22.59% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/16/zacks-brokerages-expect-miragen-therapeutics-inc-mgen-to-post-0-32-eps.html.
About Miragen Therapeutics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Get a free copy of the Zacks research report on Miragen Therapeutics (MGEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.